Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434

Brett S. Abrahams, Jeff D. Rutherford, Paul E. Mallet, Richard J. Beninger

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

While self-administration and place conditioning studies have shown that dopamine D2-like receptor agonists produce reward-related learning, the, effects of dopamine D1-like receptor agonists remain equivocal. The present study tested three dopamine D1-like receptor agonists for their ability to induce a place preference. Like control rats treated with amphetamine (2.0 mg/kg i.p.), rats treated with SKF 82958 (±-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5- tetrahydro-1-phenyl-1H-3-benzazepine hydrobromide; 0.05 but not 0.01, 0.025, 0.075, or 0.10 mg/kg s.c. and/or i.p.) during conditioning showed a significant increase in the amount of time spent on the drug-paired side during the drug free test. Neither SKF 81297 (±-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; 0.25, 0.50, 1.0, 2.0, and 4.0 mg/kg i.p.) nor SKF 77434 (±-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine hydrochloride; 0.20, 1.0, 5.0, and 10.0 mg/kg i.p.) produced place conditioning. Significant increases in locomotion were seen at some doses of all drugs. Results show for the first time that systemic administration of a dopamine D1-like receptor agonist produces a place preference and are consistent with previous findings showing that dopamine D1-like receptor activation produces reward-related learning.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalEuropean Journal of Pharmacology
Volume343
Issue number2-3
DOIs
StatePublished - Feb 19 1998
Externally publishedYes

Fingerprint

Dopamine D1 Receptors
Reward
Benzazepines
Learning
Pharmaceutical Preparations
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
Aptitude
Self Administration
Dopamine D2 Receptors
Amphetamine
Locomotion
SK&F 82958
SK&F 77434
SK&F 81297
Conditioning (Psychology)

Keywords

  • Dopamine
  • Dopamine D-like like receptor
  • Learning, reward-related
  • Place conditioning
  • SKF 77434
  • SKF 81297
  • SKF 82958

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434. / Abrahams, Brett S.; Rutherford, Jeff D.; Mallet, Paul E.; Beninger, Richard J.

In: European Journal of Pharmacology, Vol. 343, No. 2-3, 19.02.1998, p. 111-118.

Research output: Contribution to journalArticle

Abrahams, Brett S. ; Rutherford, Jeff D. ; Mallet, Paul E. ; Beninger, Richard J. / Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434. In: European Journal of Pharmacology. 1998 ; Vol. 343, No. 2-3. pp. 111-118.
@article{19b819fce38a4db5b14b1f6d07bbb3ac,
title = "Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434",
abstract = "While self-administration and place conditioning studies have shown that dopamine D2-like receptor agonists produce reward-related learning, the, effects of dopamine D1-like receptor agonists remain equivocal. The present study tested three dopamine D1-like receptor agonists for their ability to induce a place preference. Like control rats treated with amphetamine (2.0 mg/kg i.p.), rats treated with SKF 82958 (±-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5- tetrahydro-1-phenyl-1H-3-benzazepine hydrobromide; 0.05 but not 0.01, 0.025, 0.075, or 0.10 mg/kg s.c. and/or i.p.) during conditioning showed a significant increase in the amount of time spent on the drug-paired side during the drug free test. Neither SKF 81297 (±-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; 0.25, 0.50, 1.0, 2.0, and 4.0 mg/kg i.p.) nor SKF 77434 (±-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine hydrochloride; 0.20, 1.0, 5.0, and 10.0 mg/kg i.p.) produced place conditioning. Significant increases in locomotion were seen at some doses of all drugs. Results show for the first time that systemic administration of a dopamine D1-like receptor agonist produces a place preference and are consistent with previous findings showing that dopamine D1-like receptor activation produces reward-related learning.",
keywords = "Dopamine, Dopamine D-like like receptor, Learning, reward-related, Place conditioning, SKF 77434, SKF 81297, SKF 82958",
author = "Abrahams, {Brett S.} and Rutherford, {Jeff D.} and Mallet, {Paul E.} and Beninger, {Richard J.}",
year = "1998",
month = "2",
day = "19",
doi = "10.1016/S0014-2999(97)01531-8",
language = "English (US)",
volume = "343",
pages = "111--118",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434

AU - Abrahams, Brett S.

AU - Rutherford, Jeff D.

AU - Mallet, Paul E.

AU - Beninger, Richard J.

PY - 1998/2/19

Y1 - 1998/2/19

N2 - While self-administration and place conditioning studies have shown that dopamine D2-like receptor agonists produce reward-related learning, the, effects of dopamine D1-like receptor agonists remain equivocal. The present study tested three dopamine D1-like receptor agonists for their ability to induce a place preference. Like control rats treated with amphetamine (2.0 mg/kg i.p.), rats treated with SKF 82958 (±-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5- tetrahydro-1-phenyl-1H-3-benzazepine hydrobromide; 0.05 but not 0.01, 0.025, 0.075, or 0.10 mg/kg s.c. and/or i.p.) during conditioning showed a significant increase in the amount of time spent on the drug-paired side during the drug free test. Neither SKF 81297 (±-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; 0.25, 0.50, 1.0, 2.0, and 4.0 mg/kg i.p.) nor SKF 77434 (±-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine hydrochloride; 0.20, 1.0, 5.0, and 10.0 mg/kg i.p.) produced place conditioning. Significant increases in locomotion were seen at some doses of all drugs. Results show for the first time that systemic administration of a dopamine D1-like receptor agonist produces a place preference and are consistent with previous findings showing that dopamine D1-like receptor activation produces reward-related learning.

AB - While self-administration and place conditioning studies have shown that dopamine D2-like receptor agonists produce reward-related learning, the, effects of dopamine D1-like receptor agonists remain equivocal. The present study tested three dopamine D1-like receptor agonists for their ability to induce a place preference. Like control rats treated with amphetamine (2.0 mg/kg i.p.), rats treated with SKF 82958 (±-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5- tetrahydro-1-phenyl-1H-3-benzazepine hydrobromide; 0.05 but not 0.01, 0.025, 0.075, or 0.10 mg/kg s.c. and/or i.p.) during conditioning showed a significant increase in the amount of time spent on the drug-paired side during the drug free test. Neither SKF 81297 (±-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; 0.25, 0.50, 1.0, 2.0, and 4.0 mg/kg i.p.) nor SKF 77434 (±-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine hydrochloride; 0.20, 1.0, 5.0, and 10.0 mg/kg i.p.) produced place conditioning. Significant increases in locomotion were seen at some doses of all drugs. Results show for the first time that systemic administration of a dopamine D1-like receptor agonist produces a place preference and are consistent with previous findings showing that dopamine D1-like receptor activation produces reward-related learning.

KW - Dopamine

KW - Dopamine D-like like receptor

KW - Learning, reward-related

KW - Place conditioning

KW - SKF 77434

KW - SKF 81297

KW - SKF 82958

UR - http://www.scopus.com/inward/record.url?scp=0032545994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032545994&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(97)01531-8

DO - 10.1016/S0014-2999(97)01531-8

M3 - Article

VL - 343

SP - 111

EP - 118

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -